- Home
- KOSS vs GNLX Comparison
KOSS vs GNLX Comparison
Compare KOSS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- GNLX
- Stock Information
- Founded
- KOSS 1953
- GNLX 2001
- Country
- KOSS United States
- GNLX United States
- Employees
- KOSS N/A
- GNLX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- GNLX Health Care
- Exchange
- KOSS Nasdaq
- GNLX Nasdaq
- Market Cap
- KOSS 68.4M
- GNLX 81.5M
- IPO Year
- KOSS N/A
- GNLX 2023
- Fundamental
- Price
- KOSS $6.62
- GNLX $2.46
- Analyst Decision
- KOSS
- GNLX Strong Buy
- Analyst Count
- KOSS 0
- GNLX 4
- Target Price
- KOSS N/A
- GNLX $18.25
- AVG Volume (30 Days)
- KOSS 148.4K
- GNLX 80.9K
- Earning Date
- KOSS 01-30-2025
- GNLX 11-14-2024
- Dividend Yield
- KOSS N/A
- GNLX N/A
- EPS Growth
- KOSS N/A
- GNLX N/A
- EPS
- KOSS N/A
- GNLX N/A
- Revenue
- KOSS $12,092,999.00
- GNLX $8,000.00
- Revenue This Year
- KOSS N/A
- GNLX N/A
- Revenue Next Year
- KOSS N/A
- GNLX N/A
- P/E Ratio
- KOSS N/A
- GNLX N/A
- Revenue Growth
- KOSS N/A
- GNLX N/A
- 52 Week Low
- KOSS $2.27
- GNLX $1.60
- 52 Week High
- KOSS $18.73
- GNLX $12.59
- Technical
- Relative Strength Index (RSI)
- KOSS 38.21
- GNLX 48.80
- Support Level
- KOSS $6.58
- GNLX $2.25
- Resistance Level
- KOSS $7.27
- GNLX $2.57
- Average True Range (ATR)
- KOSS 0.45
- GNLX 0.19
- MACD
- KOSS -0.14
- GNLX 0.01
- Stochastic Oscillator
- KOSS 3.48
- GNLX 41.18
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.